3-hydroxykynurenine has been researched along with Parkinson Disease in 7 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "The kynurenine (KYN) pathway plays an important role in degrading molecules responsible for oxidative stress in the central nervous system (CNS), but can also have neurotoxic effects." | 1.56 | Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. ( Iwaoka, K; Kato, K; Maeda, T; Otsuka, C; Takahashi, K; Terayama, Y; Yamahara, K, 2020) |
| "In untreated patients with Parkinson's disease (PD), the total (free and conjugated) serotonin (5-HT) and dopamine (DA) concentrations in the cerebrospinal fluid decreased significantly." | 1.29 | Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. ( Abe, T; Hamato, H; Takahashi, J; Takahashi, S; Tohgi, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Iwaoka, K | 1 |
| Otsuka, C | 1 |
| Maeda, T | 1 |
| Yamahara, K | 1 |
| Kato, K | 1 |
| Takahashi, K | 2 |
| Terayama, Y | 1 |
| Robertson, DS | 1 |
| Lewitt, PA | 1 |
| Li, J | 1 |
| Lu, M | 1 |
| Beach, TG | 1 |
| Adler, CH | 1 |
| Guo, L | 1 |
| Amara, AW | 1 |
| Standaert, DG | 1 |
| Tohgi, H | 2 |
| Abe, T | 2 |
| Takahashi, S | 2 |
| Takahashi, J | 2 |
| Hamato, H | 2 |
1 review available for 3-hydroxykynurenine and Parkinson Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
6 other studies available for 3-hydroxykynurenine and Parkinson Disease
| Article | Year |
|---|---|
Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease.
Topics: Aged; Case-Control Studies; Cytokines; Female; Humans; Inflammation; Interferon-gamma; Interleukin-1 | 2020 |
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Glutathione; Humans; Kynurenine; Male; Mass Spec | 2013 |
Metabolomics and the search for biomarkers in Parkinson's disease.
Topics: Female; Humans; Kynurenine; Male; Oxidative Stress; Parkinson Disease | 2013 |
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration.
Topics: Aged; Dopamine; Humans; Hydroxyindoleacetic Acid; Kynurenine; Levodopa; Middle Aged; Parkinson Disea | 1993 |
Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms.
Topics: 5-Hydroxytryptophan; Humans; Hydroxyindoleacetic Acid; Kynurenine; Middle Aged; Parkinson Disease; R | 1993 |